Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study
Background: More than half of Chinese patients with hormone receptor positive (HR+) ductal carcinoma in situ (DCIS) are treated with mastectomy, and usually subjected to postoperative endocrine therapy (ET). Given that long-term ET can cause severe adverse effects it is important to determine the be...
Main Authors: | Nan Niu, Yinan Zhang, Yang Bai, Xin Wang, Shunchao Yan, Dong Song, Hong Xu, Tong Liu, Bin Hua, Yingchao Zhang, Jinchi Liu, Xinbo Qiao, Jiaxiang Liu, Xinyu Zheng, Hongyi Cao, Caigang Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2023-02-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/83045 |
Similar Items
-
Clinicopathological features and prognostic differences of ductal carcinoma in situ with ductal carcinoma in situ with microinvasion
by: LIU Jing, et al.
Published: (2020-07-01) -
Ductal carcinoma in situ: a challenging disease
by: Sevilay Altintas, et al.
Published: (2011-12-01) -
Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy
by: Ju-Chun Chien, et al.
Published: (2022-06-01) -
CHEST WALL RELAPSE OF DUCTAL CARCINOMA IN SITU AFTER MASTECTOMY: A CASE REPORT
by: Bektaş Kaya, et al.
Published: (2013-01-01) -
Prophylactic mastectomy for the prevention of breast cancer: Review of the literature
by: Rawan K. Alaofi, et al.
Published: (2018-07-01)